NAME,DESCRIPTION,SEQAPASS,GENE_SYMBOLS,GENE_NAMES,GENE_URLS,AOP,EVENT,HIT_CALL,TOP,SCALED_TOP,AC50,LOGAC50,BMAD,MAXMED,MAXMED_UNITS,MAXMEDCONC,CUTOFF,FLAGS,MODLACC,MODLAC10,MODLACB,STOCK_CONCENTRATION,INTENDED_TARGET_FAMILY
APR_HepG2_CellCycleArrest_1h_up,"Data from the assay component APR_HepG2_CellCycleArrest_1hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_CellCycleArrest_1h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, measures of all nuclear dna for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""arrest"".",, , , ,,,Active,0.856399902870391,1.1813779950370817,0.004524277651656472,-2.3444507505896,0.0724916078061459,0.784405868195458,log2_fold_induction,-0.397940008672038,0.724916078061459,"[""Gain AC50 < lowest conc & loss AC50 < mean conc"",""Borderline active"",""AC50 less than lowest concentration tested"",""Gain AC50 < lowest conc & loss AC50 < mean conc"",""AC50 less than lowest concentration tested"",""Borderline active""]",-2.13315188903093,-2.47783956233792,-2.61640403756558,20,cell cycle
ATG_CRE_CIS_up,"Data from the assay component ATG_CRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_CRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene CREB3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.",NP_006359.3,CREB3,cAMP responsive element binding protein 3,https://www.ncbi.nlm.nih.gov/gene/10488,,,Active,0.9523300584940646,1.3035948774645758,81.79968014573603,1.9127516054902296,0.14610828486013952,0.7936085305928949,log2_fold_induction,2,0.7305414243006976,"[""Only highest conc above baseline, active"",""Borderline active"",""Hit-call potentially confounded by overfitting""]",1.9774648009589784,1.9041051781210017,1.7934712910697057,20,dna binding
ATG_DR5_CIS_up,"Data from the assay component ATG_DR5_RAR_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_DR5_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RARA and RARB and RARG. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.","NP_000955.1|NP_001277145.1|NP_000957.1","RARA | RARB | RARG","retinoic acid receptor, alpha , retinoic acid receptor, beta , retinoic acid receptor, gamma","https://www.ncbi.nlm.nih.gov/gene/5914 , https://www.ncbi.nlm.nih.gov/gene/5915 , https://www.ncbi.nlm.nih.gov/gene/5916",,,Active,0.8455028391163835,1.4244791389587343,22.090321992452377,1.3442020462709874,0.11871045577184501,0.7045856992907233,log2_fold_induction,2,0.593552278859225,"[""Hit-call potentially confounded by overfitting"",""Borderline active""]",2.162430201426176,1.040720471526086,-0.7538804861337314,20,nuclear receptor
ATG_EGR_CIS_up,"Data from the assay component ATG_EGR_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_EGR_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene EGR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is zinc finger.",NP_001955.1,EGR1,early growth response 1,https://www.ncbi.nlm.nih.gov/gene/1958,,,Active,0.9197589198077372,1.3183307324486881,40.111121749635714,1.603264807652669,0.13953386614895374,0.9191457475151553,log2_fold_induction,2,0.6976693307447688,"[""Only highest conc above baseline, active"",""Borderline active"",""Hit-call potentially confounded by overfitting""]",1.6654050547290242,1.5934931473207905,1.4839843631716567,20,dna binding
ATG_Ets_CIS_dn,ATG_Ets_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,NP_005229.1,ETS1,v-ets avian erythroblastosis virus E26 oncogene homolog 1,https://www.ncbi.nlm.nih.gov/gene/2113,,,Active,0.49786219435815815,1.3741127718102546,81.79852317421569,1.9127454628023906,0.07246307647694375,0.4148851796840322,log2_fold_induction,2,0.3623153823847187,"[""Hit-call potentially confounded by overfitting"",""Borderline active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.9661201461635347,1.8989138399474284,1.7934651486503879,20,dna binding
ATG_HNF6_CIS_dn,ATG_HNF6_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,NP_004489.1,ONECUT1,one cut homeobox 1,https://www.ncbi.nlm.nih.gov/gene/3175,,,Active,0.503446661085597,1.4016657009156124,81.78760512863576,1.9126874915427885,0.07183548270557376,0.41953889151378293,log2_fold_induction,2,0.3591774135278688,"[""Hit-call potentially confounded by overfitting"",""Borderline active"",""Less than 50% efficacy""]",1.9622321879417655,1.8969484068494327,1.7933402353183763,20,dna binding
ATG_HSE_CIS_up,"Data from the assay component ATG_HSE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_HSE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene HSF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is heat shock protein.",NP_005517.1,HSF1,heat shock transcription factor 1,https://www.ncbi.nlm.nih.gov/gene/3297,,,Active,1.6780674627388281,3.5331051835179417,81.21521994792168,1.9096374248076586,0.09499108436211133,1.3983895527071435,log2_fold_induction,2,0.47495542181055667,"[""Only highest conc above baseline, active""]",1.8574238567470556,1.8204907115282203,1.786203736437901,20,dna binding
ATG_MRE_CIS_up,"Data from the assay component ATG_MRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_MRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene MTF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is zinc finger.",NP_005946.2,MTF1,metal-regulatory transcription factor 1,https://www.ncbi.nlm.nih.gov/gene/4520,,,Active,1.0016965654167798,1.6655191387531474,81.79131477684304,1.912707189432314,0.12028640705584168,0.8347514857671499,log2_fold_induction,2,0.6014320352792084,"[""Hit-call potentially confounded by overfitting"",""Only highest conc above baseline, active"",""Borderline active""]",1.934812120773628,1.8815309388705836,1.7934268757518521,20,dna binding
ATG_NFI_CIS_dn,ATG_NFI_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,NP_001128145.1,NFIA,nuclear factor I/A,https://www.ncbi.nlm.nih.gov/gene/4774,,,Active,0.5262876162360166,1.24925963615362,6.066382378406008,0.7829297814441285,0.08425592262892893,0.4385730137396346,log2_fold_induction,1,0.4212796131446447,"[""Only one conc above baseline, active"",""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting"",""Borderline active""]",0.8605026110524914,0.7785240323882894,0.66024223415356,20,dna binding
ATG_NRF2_ARE_CIS_up,"Data from the assay component ATG_NRF2_ARE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_NRF2_ARE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NFE2L2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.",NP_006155.2,NFE2L2,"nuclear factor, erythroid 2-like 2",https://www.ncbi.nlm.nih.gov/gene/4780,"[61,61]",[478],Active,1.489923629748945,1.9185497675988616,52.27077842937705,1.7182589677668858,0.15531769411576343,1.2416030253022772,log2_fold_induction,2,0.7765884705788172,"[""Hit-call potentially confounded by overfitting"",""Only highest conc above baseline, active""]",1.7332168892160686,1.579636645276763,1.3314154518499124,20,dna binding
ATG_Pax6_CIS_up,"Data from the assay component ATG_Pax6_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_Pax6_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PAX6. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is paired box protein.",NP_000271.1,PAX6,paired box 6,https://www.ncbi.nlm.nih.gov/gene/5080,,,Active,1.1296335590587117,1.7797298654594604,38.55902233776596,1.5861260138538187,0.12694438419923712,1.1290799491649293,log2_fold_induction,2,0.6347219209961856,"[""Only highest conc above baseline, active""]",1.5996330851705767,1.5494218471995693,1.4668448837934307,20,dna binding
ATG_PPRE_CIS_up,"Data from the assay component ATG_PPRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_PPRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARA and PPARD and PPARG. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.","NP_005027.2|NP_006229.1|NP_056953.2","PPARA | PPARD | PPARG","peroxisome proliferator-activated receptor alpha , peroxisome proliferator-activated receptor delta , peroxisome proliferator-activated receptor gamma","https://www.ncbi.nlm.nih.gov/gene/5465 , https://www.ncbi.nlm.nih.gov/gene/5467 , https://www.ncbi.nlm.nih.gov/gene/5468",,,Active,1.3054150161867235,1.457936950667563,50.12738102374411,1.7000750148734094,0.1790770191521653,1.0878458468505687,log2_fold_induction,2,0.8953850957608266,"[""Hit-call potentially confounded by overfitting"",""Only highest conc above baseline, active""]",1.8544136268679978,1.6294092582268884,1.2658800441308162,20,nuclear receptor
ATG_RORE_CIS_up,"Data from the assay component ATG_RORE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_RORE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RORA and RORB and RORC. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.","NP_599023.1|NP_008845.2|NP_005051.2","RORA | RORB | RORC","RAR-related orphan receptor A , RAR-related orphan receptor B , RAR-related orphan receptor C","https://www.ncbi.nlm.nih.gov/gene/6095 , https://www.ncbi.nlm.nih.gov/gene/6096 , https://www.ncbi.nlm.nih.gov/gene/6097",,,Active,0.9386032773642444,1.3708741322705185,81.77826672777613,1.9126379015406503,0.13693500450105905,0.782169464016804,log2_fold_induction,2,0.6846750225052953,"[""Only highest conc above baseline, active"",""Borderline active"",""Hit-call potentially confounded by overfitting""]",1.966510582884129,1.8990273052200584,1.7932999947465837,20,nuclear receptor
ATG_Sox_CIS_up,"Data from the assay component ATG_Sox_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_Sox_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene SOX1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is HMG box protein.",NP_005977.2,SOX1,SRY (sex determining region Y)-box 1,https://www.ncbi.nlm.nih.gov/gene/6656,,,Active,1.154546813137836,2.632077895652239,51.077090114064276,1.7082261473344804,0.08772892436389956,1.0042584324767212,log2_fold_induction,2,0.4386446218194978,"[""Only highest conc above baseline, active"",""Hit-call potentially confounded by overfitting""]",1.632976452903726,1.5208316632511831,1.370696020180623,20,dna binding
ATG_TCF_b_cat_CIS_dn,ATG_TCF_b_cat_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,"NP_003193.2|NP_001139746.1|NP_057353.1|NP_112573.1","TCF7 | TCF7L2 | LEF1 | TCF7L1","transcription factor 7 (T-cell specific, HMG-box) , transcription factor 7-like 2 (T-cell specific, HMG-box) , lymphoid enhancer-binding factor 1 , transcription factor 7-like 1 (T-cell specific, HMG-box)","https://www.ncbi.nlm.nih.gov/gene/6932 , https://www.ncbi.nlm.nih.gov/gene/6934 , https://www.ncbi.nlm.nih.gov/gene/51176 , https://www.ncbi.nlm.nih.gov/gene/83439",,,Active,0.9963618415468132,1.442339015068584,54.53580370232796,1.7366817177817082,0.13815917494257557,0.8303015346405729,log2_fold_induction,2,0.6907958747128778,"[""Borderline active"",""Hit-call potentially confounded by overfitting""]",1.8821000213391121,1.6762000806385287,1.344962925710337,20,dna binding
ATG_VDRE_CIS_up,"Data from the assay component ATG_VDRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_VDRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene VDR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_000367.1,VDR,"vitamin D (1,25- dihydroxyvitamin D3) receptor",https://www.ncbi.nlm.nih.gov/gene/7421,,,Active,2.1135911333641704,2.9105793105412894,48.55649978569101,1.6862473729076477,0.1452350826317871,1.7613259444767986,log2_fold_induction,2,0.7261754131589355,"[""Hit-call potentially confounded by overfitting""]",1.554491850106518,1.4118461729983223,1.239084001996637,20,nuclear receptor
BSK_3C_Vis_down,"Data from the assay component BSK_3C_Vis was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_Vis_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, loss-of-signal activity can be used to understand changes in the background control. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell morphology"" intended target family, where the subfamily is ""cell conformation"".",, , , ,,,Active,0.149999999996809,1.8943879704367006,39.99999999999999,1.6020599913279623,0,0.125,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting""]",1.6020599913279623,1.6020599913279623,1.395408323683186,20,cell morphology
BSK_BE3C_uPAR_up,"Data from the assay component BSK_BE3C_uPAR was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_uPAR_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAUR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""plasmogen activator"".",NP_002650.1,PLAUR,"plasminogen activator, urokinase receptor",https://www.ncbi.nlm.nih.gov/gene/5329,,,Active,0.05130134190441282,0.45108527336296916,10,1,0.0379095667965,0.122,log10_fold_induction,1,0.11372870038949999,"[""Borderline active"",""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active"",""Less than 50% efficacy""]",1,1,-1.1404681333371598,20,cytokine
BSK_hDFCGF_IP10_down,"Data from the assay component BSK_hDFCGF_IP10 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_IP10_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL10. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_001556.2,CXCL10,chemokine (C-X-C motif) ligand 10,https://www.ncbi.nlm.nih.gov/gene/3627,,,Active,0.11759999125639517,1.4538984389339642,40.000000000000014,1.6020599913279625,0.0269619913164,0.098,log10_fold_induction,1.60205999132796,0.0808859739492,"[""Less than 50% efficacy"",""Only one conc above baseline, active"",""Borderline active"",""Hit-call potentially confounded by overfitting""]",1.6020599913279625,1.6020599913279625,1.3953599224146698,20,cytokine
BSK_hDFCGF_MMP1_up,"Data from the assay component BSK_hDFCGF_MMP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_MMP1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene MMP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""matrix metalloproteinase"".",NP_002412.1,MMP1,matrix metallopeptidase 1 (interstitial collagenase),https://www.ncbi.nlm.nih.gov/gene/4312,,,Active,0.11400587954457135,1.4340689775379518,40.000000000000014,1.6020599913279625,0.026499394689809996,0.114,log10_fold_induction,1.60205999132796,0.07949818406942999,"[""Only one conc above baseline, active"",""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting""]",1.6020599913279625,1.6020599913279625,0.8615085692613326,20,protease
LTEA_HepaRG_CYP2B6_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000758.1,CYP2B6,"cytochrome P450, family 2, subfamily B, polypeptide 6",https://www.ncbi.nlm.nih.gov/gene/1555,,,Active,1.89345635788506,2.51169473622558,0.8378536081487226,-0.0768318557456928,0.251285361310856,1.93635671260132,log2_fold_induction,1.47712125471966,0.753856083932568,,-0.218840672625968,-0.218840672625968,-0.831917965675255,20,cyp
LTEA_HepaRG_CYP4A11_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000769.2,CYP4A11,"cytochrome P450, family 4, subfamily A, polypeptide 11",https://www.ncbi.nlm.nih.gov/gene/1579,,,Active,1.13663445322028,1.7781685299045096,96.52632211111592,1.98464575882372,0.213072127136213,0.64840243880763,log2_fold_induction,2,0.639216381408639,"[""Only highest conc above baseline, active"",""Borderline active"",""Hit-call potentially confounded by overfitting"",""Only highest conc above baseline, active"",""Hit-call potentially confounded by overfitting"",""Borderline active""]",1.99826155203894,1.99826155203894,1.86536543513509,20,cyp
LTEA_HepaRG_CYP7A1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000771.2,CYP7A1,"cytochrome P450, family 7, subfamily A, polypeptide 1",https://www.ncbi.nlm.nih.gov/gene/1581,,,Active,2.42520676914655,4.51519166172917,68.07095512272711,1.83296184435544,0.179040518530855,1.5596183914309,log2_fold_induction,2,0.537121555592565,"[""Noisy data"",""Noisy data""]",0.90544189416396,0.90544189416396,0.211786698721823,20,cyp
LTEA_HepaRG_MMP3_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_002413.1,MMP3,"matrix metallopeptidase 3 (stromelysin 1, progelatinase)",https://www.ncbi.nlm.nih.gov/gene/4314,,,Active,1.26141415024964,1.3429135888180854,36.469457269133855,1.56192930028186,0.313103826573539,1.26103407652512,log2_fold_induction,2,0.939311479720617,"[""Hit-call potentially confounded by overfitting"",""Borderline active"",""Hit-call potentially confounded by overfitting"",""Borderline active""]",1.62003178472663,1.62003178472663,1.44264781358974,20,protease
LTEA_HepaRG_THRSP_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_003242.1,THRSP,thyroid hormone responsive,https://www.ncbi.nlm.nih.gov/gene/7069,,,Active,2.22567707418267,2.2902095547182726,190.52139661018367,2.27994375643116,0.323940818661091,1.30224837221841,log2_fold_induction,2,0.971822455983273,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.95644630572555,1.95644630572555,-0.509630717373307,20,growth factor
NVS_ENZ_hCASP10,"Data from the assay component NVS_ENZ_hCASP10 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCASP10, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CASP10. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""cysteine protease"".",NP_116756.2,CASP10,"caspase 10, apoptosis-related cysteine peptidase",https://www.ncbi.nlm.nih.gov/gene/843,,,Active,33.5423759005925,1.6771187950296251,16.580010915070286,1.21958481212217,1.74738543778287,27.9519799319118,percent_activity,1.69897000433602,20,"[""Borderline active"",""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting"",""Borderline active"",""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting""]",1.41299893347922,0.383176793457421,0.129651640827806,20,protease
NVS_NR_bPR,"Data from the assay component NVS_NR_bPR was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_bPR, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene PGR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",NP_001192285.1,PGR,progesterone receptor-like,https://www.ncbi.nlm.nih.gov/gene/100848466,,,Active,34.1036656290479,1.3677732214364668,19.789835285135986,1.29644217949926,4.15561891578676,34.0829156346095,percent_activity,1.69897000433602,24.9337134947206,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.35074524250271,1.26651233206003,1.17716060060414,20,nuclear receptor
TOX21_AP1_BLA_Agonist_ch2,"Data from the assay component TOX21_AP1_BLA_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AP1_BLA_Agonist_ch2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene JUN|FOS|JUN. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,75.2623346448361,3.5321095172457087,57.023404759327114,1.75605314464729,3.55134017774949,62.534068817,percent_activity,1.90308998699194,21.3080410664969,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.66648418950794,1.58228518556958,1.54422113812264,20,channel 2
TOX21_AP1_BLA_Agonist_ratio,"Data from the assay component TOX21_AP1_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AP1_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene JUN|FOS|JUN. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.",NP_002219.1,"JUN | FOS|JUN","jun proto-oncogene , FBJ murine osteosarcoma viral oncogene homolog|jun proto-oncogene","https://www.ncbi.nlm.nih.gov/gene/3725 , https://www.ncbi.nlm.nih.gov/gene/4029",,,Active,73.843740320399,3.6921870160199495,64.07831784061273,1.8067111022939,2.7369041511147,59.7826681866,percent_activity,1.90308998699194,20,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.74143599240783,1.66970612427069,1.66189006552292,20,dna binding
TOX21_DT40,"Data from the assay component TOX21_DT40 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_DT40, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in the viability. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint.",, , , ,,,Active,135.353279998641,5.63957475153432,76.31832996107867,1.88262885833357,4.0001030208237,109.1015260016,percent_activity,1.95424250943932,24.0006181249422,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.79931908402715,1.7561342070704,1.76334854141346,20,cell cycle
TOX21_DT40_100,"Data from the assay component TOX21_DT40_100 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_DT40_100, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in the viability as they relate to the gene Ku70 - Rad54 (-/-). Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA repair family.",,"RAD54L | XRCC6P1","RAD54 like (S. cerevisiae) , X-ray repair cross complementing 6 pseudogene 1","https://www.ncbi.nlm.nih.gov/gene/8438 , https://www.ncbi.nlm.nih.gov/gene/387703",,,Active,151.357443670361,7.017232162228116,77.7166254092868,1.89051393451725,3.59489896137582,110.6648668525,percent_activity,1.95424250943932,21.5693937682549,"[""Noisy data"",""Only highest conc above baseline, active"",""Noisy data"",""Only highest conc above baseline, active""]",1.79308933817634,1.75112728559031,1.77123362044331,20,cell cycle
TOX21_DT40_657,"Data from the assay component TOX21_DT40_657 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_DT40_657, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene Rev3. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA repair family.",,REV3L,"REV3 like, DNA directed polymerase zeta catalytic subunit",https://www.ncbi.nlm.nih.gov/gene/5980,,,Active,146.088302457227,5.575460549599376,76.82496445261744,1.88550236797774,4.36700254498032,109.6880690696,percent_activity,1.95424250943932,26.2020152698819,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.80294797678721,1.75968912657322,1.76622199751762,20,cell cycle
TOX21_HSE_BLA_agonist_ch2,"Data from the assay component TOX21_HSE_BLA_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_HSE_BLA_Agonist_ch2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene HSF1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,37.6901944652257,1.884509723261285,43.12737452155895,1.63475302027195,0.96226530123801,44.0119427498,percent_activity,1.90308998699194,20,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.64141519399519,1.49960232044852,1.5154727039479,20,channel 2
TOX21_HSE_BLA_agonist_ratio,"Data from the assay component TOX21_HSE_BLA_Agonist_ratio was analyzed into 1 assay endpoint.  This assay endpoint, TOX21_HSE_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene HSF1.  Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity.  To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is heat shock protein.",NP_005517.1,HSF1,heat shock transcription factor 1,https://www.ncbi.nlm.nih.gov/gene/3297,,,Active,47.081935773569,2.35409678867845,71.50322827628072,1.85432565006576,0.91844270028357,33.2348497404,percent_activity,1.90308998699194,20,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.83786943598065,1.70351424805705,1.73504533226747,20,dna binding
TOX21_PPARd_BLA_Antagonist_ch1,"Data from the assay component TOX21_PPARd_BLA_Antagonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PPARd_BLA_Antagonist_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter,increased activity can be used to understand changes in the reporter gene as they relate to the gene PPARD. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,39.6410414440857,1.1682208274730683,37.71133642777724,1.57647192336093,5.65547205229335,36.6696915028,percent_activity,1.90308998699194,33.9328323137601,"[""Borderline active"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Borderline active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.69392771163632,1.55736176931152,1.43168652559728,20,channel 1
TOX21_PPARd_BLA_Antagonist_ch2,"Data from the assay component TOX21_PPARd_BLA_Antagonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PPARd_BLA_Antagonist_ch2, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene PPARD. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,117.016787300217,1.9904292908993684,67.61801902292893,1.83006244327073,9.79828722001836,92.4106349903,percent_activity,1.90308998699194,58.7897233201102,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.83058452232958,1.77076823650183,1.71077904122849,20,channel 2
TOX21_PPARd_BLA_antagonist_ratio,"Data from the assay component TOX21_PPARd_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PPARd_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene PPARD. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_006229.1,PPARD,peroxisome proliferator-activated receptor delta,https://www.ncbi.nlm.nih.gov/gene/5467,"[36,36]",,Active,87.7205654055719,2.417284448515948,45.59528840382085,1.65891996709555,6.04814805441609,81.3637498131,percent_activity,1.90308998699194,36.2888883264965,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.63998783926745,1.58595539851361,1.53963965272906,20,nuclear receptor
TOX21_PR_BLA_Agonist_viability,"TOX21_PR_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,67.7189025840958,2.0372539185208236,83.03737567804448,1.91927361523278,5.54004764031117,42.8978137616,percent_activity,1.95424250943932,33.240285841867,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.91728797971015,1.85830166465635,1.79999330150503,20,cell cycle
TOX21_PR_BLA_Antagonist_ratio,"Data from the assay component TOX21_PR_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity an be used to understand changes in the reporter gene as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",NP_000917.3,PGR,progesterone receptor,https://www.ncbi.nlm.nih.gov/gene/5241,,,Active,46.1173156626111,2.305865783130555,51.44230009507029,1.71132037858383,2.51198214229767,45.6103267754,percent_activity,1.95424250943932,20,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.69683306071936,1.622665398965,1.59204006442579,20,nuclear receptor
TOX21_PR_BLA_Antagonist_viability,"TOX21_PR_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,41.0090220837727,1.2472680106305796,44.95211479283498,1.65275012813274,5.47984631667627,42.7213749728,percent_activity,1.95424250943932,32.8790779000576,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.72860414265288,1.63093682794492,1.53346980443987,20,cell cycle
TOX21_RXR_BLA_Agonist_ch2,"Data from the assay component TOX21_RXR_BLA_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_RXR_BLA_Agonist_ch2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene RXRA. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,88.2194126307522,2.9982383967349446,38.55952854510085,1.58613171528492,4.90395808901334,42.25952101,percent_activity,1.47712125471966,29.42374853408,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.26022850765703,0.828776508898783,0.551727964189671,20,channel 2
TOX21_RXR_BLA_Agonist_ratio,"Data from the assay component TOX21_RXR_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_RXR_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene RXRA. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where subfamily is NF-kappa B.",NP_002948.1,RXRA,"retinoid X receptor, alpha",https://www.ncbi.nlm.nih.gov/gene/6256,,,Active,50.1176982763355,2.505884913816775,34.599967941285705,1.53907569639598,2.27839049691729,25.3871298704,percent_activity,1.47712125471966,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.31569293314175,0.531968404529255,0.34013767129412,20,dna binding
TOX21_SHH_3T3_GLI3_Agonist_viability,"TOX21_SHH_3T3_GLI3_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,110.816019332076,5.5408009666038,74.44636187474015,1.87184347903472,2.74374658540332,89.9535496774,percent_activity,1.95424250943932,20,"[""Only highest conc above baseline, active"",""Cell viability assay fit with gnls winning model"",""Only highest conc above baseline, active"",""Cell viability assay fit with gnls winning model""]",1.78970192072176,1.73489126925257,1.75256316530439,20,cell cycle
TOX21_SHH_3T3_GLI3_Antagonist,"Data from the assay component TOX21_SHH_3T3_GLI3_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_SHH_3T3_GLI3_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene GLI3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function.",,SHH,sonic hedgehog,https://www.ncbi.nlm.nih.gov/gene/6469,,,Active,73.6769076983087,1.6668139466896479,31.001831697750653,1.49138735424475,7.36703975915985,72.1692063378,percent_activity,1.95424250943932,44.2022385549591,,1.51338676990967,1.44538340334247,1.37210704055187,20,dna binding
TOX21_SHH_3T3_GLI3_Antagonist_viability,"TOX21_SHH_3T3_GLI3_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,67.3624060668588,3.36812030334294,49.17658568010896,1.69175837247584,2.48726544475101,65.0662529217,percent_activity,1.95424250943932,20,,1.64495772179845,1.57868445482326,1.57247759871469,20,cell cycle
TOX21_VDR_BLA_Agonist_viability,"TOX21_VDR_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,54.9620535099001,2.0214072950948347,38.91400504147469,1.5901059308269,4.53166577259249,54.8034773154,percent_activity,1.90308998699194,27.1899946355549,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.58895606140041,1.52969649415854,1.47082561632458,20,cell cycle